HOTsPOT - Novel upconversion nanoparticles for multimodal therapy of melanoma: pHOtothermal Therapy, PhOtodynamic therapy and chemoTherapy
funding type Fundação para a Ciência e a Tecnologia
programme 02/SAICT/2017
alternative reference POCI-01-0145-FEDER-031794
research group(s) 1 - inorganic functional nanomaterials and organic-inorganic hybrids;
5 - biomedical and biomimetic materials;
department Biology (DB)
execution dates 2018-08-10 - 2021-08-09 ( 36 Months )
MOTIVATION: Melanoma is the most aggressive form of skin cancer and one of the most challenging malignancies to treat with a steeply rising incidence and a poor prognosis in advanced stages. Conventional clinical treatment of melanoma often fails in tumor complete eradication, due to the low response rates to single therapies, chemotherapy side effects and recalcitrance to traditional chemotherapy and radiotherapy. Therefore, inspired by the unique proprieties of near infrared light (NIR) excitable upconversion nanoparticles (UCNPs) and the recent advances in its synthesis, functionalization and successful applications to tumor therapy, we propose the development of novel upconversion nanoplatforms for multimodal therapy of melanoma.
AIMS: This project aims the developing of multimodal nanoplatforms for the treatment of melanoma skin cancer. Our approach is based on the development of NIR excitable upconversion nanoplatforms that combine in a single platform, targeted generation of i) hyperthermia, ii) reactive oxygen species and iii) antitumor drug delivery, respectively in a context of photothermal therapy (PTT), photodynamic therapy (PDT) and chemotherapy.
STRATEGY: We propose the development of nanoplatforms formed by UCNPs with a shell of mesoporous silica to allow the load of photosensitisers (PS) and anticancer drugs that, under NIR excitation will produce PTT, PDT and release of anticancer drug in the tumor (chemotherapy). These nanoplatforms will then be tested in vitro with melanoma cell lines to: i) evaluate the effect of each nanoplatform on cell viability upon NIR irradiation; ii) evaluate the underlying cytotoxic mechanisms due to single and combined therapies in the different melanoma cells lines; iii) seek for synergistic effects of combined therapies in the melanoma cell lines. The therapeutic efficacy of the nanoplatforms will then be investigated in vivo in mice grafted with melanoma tumors to evaluate the efficacy of combined therapies in suppressing the tumor growth.
NOVELTY: This project will develop new therapeutic approaches for melanoma, in the hope of contributing to increase the overall response rates, reduce the dose of antitumor drugs and, their side effects and decrease tumor resilience to traditional therapies. This triple therapeutic approach presented in this proposal is totally innovative for melanoma therapy.
/local pi
Helena Cristina Correia de Oliveira (CESAM)
ciceco status Partner
proponent institution Universidade de Aveiro (UA)
partner institution(s) Universidade de Lisboa
industrial partner(s) no
international partner(s) no
total budget 235.080€